pharma-and-clinical-pharmacy-congress-2016_tracks

14 / 21

Notes:
Page 42
Pharma & Clinical Pharmacy Congress 2016
November 07-09, 2016
Volume 5 Issue 4(Suppl) Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal
conferenceseries .com
November 07-09, 2016 Las Vegas, Nevada, USA
4th International
Pharma & Clinical Pharmacy Congress
Daniel Roberto Magdaleno Rodriguez et al., Clin Pharmacol Biopharm 2016, 5:4(Suppl)
Efficiency and safety of combining silybin, lipoteichoic acid and selenomethionine in the treatment
of non-alcoholic fatty liver
Daniel Roberto Magdaleno Rodriguez, Avila Lamadrid Pamela Georgina, Sanchez Flores Jessica, Cortes Moreno Gabriela Yanet and Lara Padilla Eleazar
Instituto Politecnico Nacional, Mexico
Obesity has become a public global health, we cannot lose sight that this disease has reached epidemic global proportions,
which is why theWorld Health Organization (WHO) calls obesity as the epidemic of the century. The purpose of this study
was to evaluate the efficacy and safety of the combination of silymarin, selenomethionine and alpha lipoteichoic acid in adult
patients with non-alcoholic fatty liver using different dosages, comparing changes in patients receiving doses every 8 hours
against the patients that received doses every 12 hours. It was evaluated the biochemical changes through blood, morphological
determinations by ultrasound and anthropometric measurements. It was a longitudinal, prospective and comparative study
during 12 weeks. This study was conducted under 88 exogenous obese patients, aged between 18 and 60 years of both sexes
with Body Mass Index (BMI) between 30 and 45 kg/m2 and diagnosed with fatty liver confirmed by ultrasound with sub-
clinical alterations in liver enzymes. Patients were randomized into two groups of 44 subjects each and were administered for
three months the combination of silymarin, selenomethionine and alpha lipoteichoic acid with dosage of one capsule every 8
hours (group 1) and every 12 hours (group 2).
Biography
Daniel Roberto Magdaleno Rodriguez is currently a Medical student of Superior School of Medicine (Escuela Superior de Medicina) at Instituto Politécnico
Nacional, Mexico. He is a Junior Researcher who has been working at the Obesity Center of the School since 2013 on different research lines regarding obesity,
diabetes, fatty liver, metabolic syndrome and hypertension. His recent research is focused on drug effectiveness and security for obesity and fatty liver treatment.
He is also the CEO and Founder of AIMEDS A.C.